Drugs / RG6289
last change Jan 2026 re-read 2 minutes ago

RG6289

Developed for
familial Alzheimer disease
Investigated by
Banner Health · National Institute on Aging (NIA) · Universidad de Antioquia

Trials 1 · a red edge is where a trial was stopped

20262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT06996730 Jan 2026 → Jun 2030 expected early-onset autosomal dominant Alzheimer disease Banner Health Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RG6289 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06996730
Route Oral Oral tablet” NCT06996730